ISDA

Deposition Date 2019-05-08

Release Date 2019-07-17

Last Version Date 2024-01-24

Entry Detail

PDB ID:

6RN8

Keywords:

TRANSFERASE

Title:

RIP2 Kinase Catalytic Domain complex with 2(4[(1,3benzothiazol5yl)amino]6(2methylpropane2sulfonyl)quinazolin7yl)oxy)ethyl phosphate

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.69 Å

R-Value Free:

0.21

R-Value Work:

0.17

R-Value Observed:

0.17

Space Group:

P 32 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Receptor-interacting serine/threonine-protein kinase 2
Gene (Uniprot):RIPK2
Chain IDs:A, B
Chain Length:311
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:O43353 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

K9T

Primary Citation

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.

Haile, P.A, Casillas, L.N, Votta, B.J, Wang, G.Z, Charnley, A.K, Dong, X, Bury, M.J, Romano, J.J, Mehlmann, J.F, King, B.W, Erhard, K.F, Hanning, C.R, Lipshutz, D.B, Desai, B.M, Capriotti, C.A, Schaeffer, M.C, Berger, S.B, Mahajan, M.K, Reilly, M.A, Nagilla, R, Rivera, E.J, Sun, H.H, Kenna, J.K, Beal, A.M, Ouellette, M.T, Kelly, M, Stemp, G, Convery, M.A, Vossenkamper, A, MacDonald, T.T, Gough, P.J, Bertin, J, Marquis, R.W.Show

J.Med.Chem. 62 6482 6494 (2019)

PMID: 31265286 DOI: 10.1021/acs.jmedchem.9b00575

Abstact

RIP2 kinase has been identified as a key signal transduction partner in the NOD2 pathway contributing to a variety of human pathologies, including immune-mediated inflammatory diseases. Small-molecule inhibitors of RIP2 kinase or its signaling partners on the NOD2 pathway that are suitable for advancement into the clinic have yet to be described. Herein, we report our discovery and profile of the prodrug clinical compound, inhibitor 3, currently in phase 1 clinical studies. Compound 3 potently binds to RIP2 kinase with good kinase specificity and has excellent activity in blocking many proinflammatory cytokine responses in vivo and in human IBD explant samples. The highly favorable physicochemical and ADMET properties of 3 combined with high potency led to a predicted low oral dose in humans.

Legend

Protein

Chemical

Disease

Primary Citation of related structures